Recursion Pharmaceuticals Prices $200 Million Stock Offering
The Salt Lake City-based biotech firm is issuing over 61 million shares to raise capital for its operations.
Updated on Oct. 15, 2026 in Biotech
Live Poll
Is now a good time for individual investors to buy shares in clinical-stage biotech companies?
Recursion Pharmaceuticals has priced an underwritten public offering of 61,540,000 shares of its Class A common stock at $3.25 per share. The company expects to generate approximately $200 million in gross proceeds from the sale.
Why it matters
This capital raise provides Recursion Pharmaceuticals with additional funding to support its ongoing drug discovery and research initiatives. The offering follows a registration statement that was previously declared effective in early 2025.
The offering includes 61,540,000 shares of Class A common stock priced at $3.25 per share, resulting in total expected gross proceeds of approximately $200 million.
The players
Recursion Pharmaceuticals
Recursion Pharmaceuticals is a clinical-stage biotechnology company that utilizes artificial intelligence and machine learning to accelerate the discovery of new medicines.
The details
The offering is being managed by four joint bookrunning managers and one lead manager under a registration statement filed on Form S-3. The company, which maintains headquarters in Salt Lake City, also operates facilities in locations including New York and London.
Timeline
February 12, 2025: Registration statement became effective.
October 15, 2026: Pricing of stock offering was announced.
October 16, 2026: Expected closing of the offering.
The Tech Race
This financial move supports the broader evolution of AI-driven drug discovery, a sector where companies like Recursion Pharmaceuticals compete to replace traditional, slower laboratory screening methods. Scaling these computational platforms is essential for maintaining a competitive edge in modern biotech research.
For investors, this offering represents a change in the total number of outstanding shares and potential equity dilution. The capital influx aims to accelerate the company's research pipeline, which could lead to future breakthroughs in therapeutic development.
The takeaway
The successful pricing of this large share offering indicates significant market interest in the application of AI to pharmaceutical research. Investors should monitor how the company allocates these funds to meet its stated clinical research goals.
What happens next
The offering is expected to officially close on or about October 16, 2026.
Further reading
For more information on the evolving landscape of drug development, visit the Biotech section.
More information
View the formal offering documents on the SEC website for filing access.
Live Poll
Is now a good time for individual investors to buy shares in clinical-stage biotech companies?
